Compare Summit Therapeutics Inc (SMMT) vs S&P500 ETF (SPY) Price & Performance

Summit Therapeutics IncTrade

S&P500 ETFTrade

Price performance (Past 24H)

Key statistics

Summit Therapeutics Inc vs S&P500 ETF — how do they compare? Summit Therapeutics Inc trades at $14.57 (market cap $10.48B), while S&P500 ETF trades at $748.04. The key difference: S&P500 ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

	SMMT	SPY
Market Cap	$10.48B	—
Sector	Health	—
52-Week High	$29.32	$759.55
52-Week Low	$13.05	$621.75
Enterprise Value	$9.90B	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

SMMT

View details →

SPY

Vanguard's VEA ETF offers low-cost developed market exposure beyond the U.S., balancing diversification and risk.24/7 Wall Street · 6 hours agoNeutral John Hancock Financial Opportunities Fund offers 6.5% growing dividend, beating S&P 500 and financial ETFs.Forbes · 13 hours agoBullish XLK ETF hides high concentration risk in top tech stocks despite low fees.24/7 Wall Street · 1 day agoNeutral View details →

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

About S&P500 ETF

The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.